2018-09-14T13:42:51-05:00 2017-12-31 454060696 CCA LLP 2300 Contra Costa Blvd Ste 220 Pleasant Hill CA 94523 990 2017-01-01 943473864 SENS Foundation Inc SENS 6503361780 110 Pioneer Way No J Mountain View CA 94041 Michael Kope President/CEO 6503361780 2018-09-14 1 CCA LLP P00587987 9256852911 2018-08-29 74.95.5.201 2018-09-14 13:42:50 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 11C41341E2825BA9C348AF826C977EBB3B18B533 2017 2018-06-14 16:35:46Z Sens Research Foundation Inc Michael Kope 110 Pioneer Way No J Mountain View CA 94041 8057919 0 X WWW.SENS.ORG X 2009 CA Develop, promote and ensure widespread access to rejuvenation biotechnologies. 10 9 19 11 0 0 2684540 7840321 10559 0 3908 28016 2556 3002 2701563 7871339 911907 1418585 0 0 1567225 1393832 0 0 260543 1513936 1113258 3993068 3925675 -1291505 3945664 2343090 6675404 271358 327923 2071732 6347481 X SENS Research Foundation works to research, develop and promote comprehensive regenerative medicine solutions for the diseases and disabilities of aging. The research is governed by a strategic agenda to demonstrate the feasibility of rejuvenation biotechnologies, as a natural extension of regenerative medicine as applied to aging, and therefore drive broader involvement. 0 0 1010512 The intramural research program is carried out in the Organization's Mountain View facility by employees of the Organization. The program is comprised of three (3) separate lines of research: Cancer, Mitochondrial mutations, and Lysosomal storage. The Lysosomal project is ongoing part-time at the Research Center. The Cancer line of research screened a wide range of drug candidates, looking for therapeutic candidates for their research after filing their patent, and the project was completed at the end of Q3 in 2017. The Mitochondrial mutations line of research has completed proof of concept and is moving ahead with their work, presenting their findings at conferences internationally. 889014 880116 Extramural Research - the extramural research program funds some of the most prestigious institutions around the world. There are currently 5 Extramural Research projects ongoing. Funding for this program continues to be prioritized for projects that meet our company mission and are currently being unaddressed in our intramural research program. 772789 538469 SRF Education - As part of its mission, the Organization is committed to educating students and the public about rejuvenation biotechnologies. The Organization's student program, SRF Education Academic Initiative, is committed to educating students and the public. SRF Education operates a summer internship program that places 12 undergraduate students at the SRF Research Center and outside institutions. A sub-program of SRF Education is the Alliance program, which funds PhD and Post-Doctoral students at Oxford University. The Education program continues to grow in size and outreach capacities. 32357 3002 Educational Conferences - In addition to participation in a variety of scientific and public engagements, the Organization organizes its own conferences and events. These include the Rejuvenation Biotechnology conference in the Bay area of California, as well as a variety of roundtable symposiums. This outreach is intended to inform both the scientific community and the general public about damage repair strategies for improving healthcare. 546005 Other programs - The Organization conducts other programs related to the mission of the organization. 578362 3002 3250677 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 25 0 1 19 1 0 0 0 0 0 0 0 0 0 0 X 10 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X The Organization 6503361780 110 Pioneer Way J Mountain View CA 94041 Barbara Logan Chairperson 1.00 X X 0 0 0 Kevin Perrott Treasurer 1.00 X X 0 0 0 Bill Liao Secretary 1.00 X X 0 0 0 Kevin Dewalt Director 1.00 X 0 0 0 Michael Boocher Director 1.00 X 0 0 0 Jonathan Cain Director 1.00 X 0 0 0 James O'Neill Director 1.00 X 0 0 0 Frank Schuler Director 1.00 X 0 0 0 Blake Masters Director 1.00 X 0 0 0 Michael Kope President/CEO 50.00 X X 190335 0 5710 Aubrey de Grey Chief Science Officer 50.00 X 73000 0 0 Matthew O'Connor VP Research 40.00 X 102399 0 0 365734 0 5710 2 0 1 0 110 Pioneer Way LLC 16821 Frank Ave Los Gatos CA 95032 Rent 211896 David Brindley ISIS Flat 45-53 Iffley Road Oxford UK OX41ED Contract Services 152223 Kaiser Permanente 3100 Thornton Ave Burbank CA 91504 Health Insurance 114031 3 X 7840321 4829100 7840321 12583 12583 202013 186580 15433 15433 15433 Publication sales 900099 3002 3002 3002 7871339 3002 0 28016 837556 837556 34200 34200 546829 546829 263335 114230 59480 89625 885136 717778 82410 84948 24289 16540 4257 3492 123473 85455 17782 20236 97599 70514 12512 14573 20737 15506 5231 60835 60835 322055 240703 73984 7368 10450 5006 911 4533 5609 23 5586 230361 187660 20230 22471 110426 104620 4560 1246 88343 79992 8351 71730 68297 3433 14050 14050 Equipment and supplies 95267 95267 Small computer equipmen 20720 2122 15968 2630 Bad debt expense 15000 11349 3651 Telephone and telecommu 10599 325 10274 37076 16705 10950 9421 3925675 3250677 414455 260543 1987853 1509888 2395 116065 580 501972 424812 148890 77160 5002617 90282 82764 2343090 6675404 271358 327923 271358 327923 X 930925 5766079 1140807 581402 2071732 6347481 2343090 6675404 X 3945664 330085 X X 0 1 X 1 0 X 1616007 1650337 1429790 2684540 7840321 15220995 1616007 1650337 1429790 2684540 7840321 15220995 7605453 7615542 7822 5600 6817 3908 28016 52163 -1192 7081 5889 15279047 496776 0.49840 0.40840 X 422681 347467 75214 79291 77345 1946 77160 Crypto currency 5002617 F 5002617 X 8201424 330085 330085 7871339 0 7871339 3925675 0 3925675 0 3925675 Part X, Line 2: The Organization evaluates its uncertain tax positions and will recognize a loss contingency when it is probable that a liability has been incurred as of the date of the financial statements and the amount of the loss can be reasonably estimated. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount recognized. As of December 31, 2017, management did not identify any uncertain tax positions. Part XI, Line 2d - Other Adjustments: Unrealized gain on crypto currency exchange 330,085. 0 0 0 0 0 0 0 0 0 0 Europe Research Grant 416552 Wire Europe Research Grant 194718 Wire Europe Research Grant 19703 Wire Europe Return of Research Grant -124258 Wire 3 Contract research Research Grant 3 40115 Cash Wire 0 0 0 0 0 0 1 Buck Institute for Research on Aging 8001 Redwood Blvd Novato CA 94945 943030609 575500 Research grant Yale University PO Box 208241 New Haven CT 06520 060646973 192279 Research grant Wake Forest University Health Sciences Medical Center Blvd WinstonSalem NC 27157 223849199 49556 Research grant The Regents of the University of CA 1111 Franklin Street 6th Floor Oakland CA 94607 943067788 501(c)(3) 10125 Research grant Rice University 6100 Main St MS 317 Houston TX 77005 771109620 7696 Research grant Sanford-Burnham Medical Research Inst 10901 N Torrey Pines Rd La Jolla CA 92037 510197108 501(c)(3) 1200 Research grant The Scripps Research Institute 10550 N Torrey Pines Rd La Jolla CA 92037 330435954 501(c)(3) 600 Research grant Brigham and Women's Hospital 75 Francis Street Boston MA 02115 042312909 600 Research grant Research grants 5 34200 Part I, Line 2: The Organization monitors grants at three month intervals. We require interim research reports every three months, which are submitted with the next payment invoice. At the conclusion of each research contract, we require a comprehensive research report and a financial accounting that details how the grant was spent. X X 0 0 0 0 0 0 0 0 0 Michael Kope President/CEO 190335 0 0 0 0 0 5710 0 0 0 196045 0 0 0 X 9110 156568 FMV X Crypto currency 3551 4672532 FMV 0 0 0 Part I, Column (b): In column b, the Organization is reporting the number of units received that year. Form 990, Part VI, Section B, line 11b The form 990 is reviewed by the president and the the director of operations and presented to the board prior to filing. Form 990, Part VI, Section B, line 12c A formal conflict of interest policy has been adopted by the organization. The policy is reviewed and reaffirmed annually. Form 990, Part VI, Section B, line 15 The president's salary was determined through the budget process by the board of directors. The board used comparable data for determining salaries of all key employees Form 990, Part VI, Section C, line 18 The forms 1023 and 990 are available at the organization's offices upon request. Form 990, Part VI, Section C, line 19 All governing documents, the conflict of interest policy and the financial statements are available at the organization's offices upon request Form 990, Part VIII, Line 1g During the year, the Organization received several crypto currency contributions made by anonymous donors totalling $2,318,255. This amount is included as part of total contributions reported on Part VIII, Line 1g. As these contributions were made anonymously, no other information is available to be disclosed on Schedule B. Form 990, Part XI, line 9: Unrealized gain on crypto currency exchange 330,085. Form 990, Part XII, Line 2c The Organization's audit committee is charged with the responsibility of overseeing the audit and the work of the independent auditors. This process has not changed from prior years.